Castration-resistant prostate cancer: AUA guideline

Michael S. Cookson, Bruce J. Roth, Philipp Dahm, Christine Engstrom, Stephen J. Freedland, Maha Hussain, Daniel W. Lin, William T. Lowrance, Mohammad H Murad, William K. Oh, David F. Penson, Adam S. Kibel

Research output: Contribution to journalArticle

166 Citations (Scopus)

Abstract

Purpose: This Guideline is intended to provide a rational basis for the management of patients with castration-resistant prostate cancer based on currently available published data. Materials and Methods: A systematic review and meta-analysis of the published literature was conducted using controlled vocabulary supplemented with keywords relating to the relevant concepts of prostate cancer and castration resistance. The search strategy was developed and executed by reference librarians and methodologists to create an evidence report limited to English-language, published peer-reviewed literature. This review yielded 303 articles published from 1996 through 2013 that were used to form a majority of the guideline statements. Clinical Principles and Expert Opinions were used for guideline statements lacking sufficient evidence-based data. Results: Guideline statements were created to inform clinicians on the appropriate use of observation, androgen-deprivation and antiandrogen therapy, androgen synthesis inhibitors, immunotherapy, radionuclide therapy, systemic chemotherapy, palliative care and bone health. These were based on six index patients developed to represent the most common scenarios encountered in clinical practice. Conclusions: As a direct result of the significant increase in FDA-approved therapeutic agents for use in patients with metastatic CRPC, clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision-making more complex. Given the rapidly evolving nature of this field, this guideline should be used in conjunction with recent systematic literature reviews and an understanding of the individual patient's treatment goals. In all cases, patients' preferences and personal goals should be considered when choosing management strategies.

Original languageEnglish (US)
Pages (from-to)429-438
Number of pages10
JournalJournal of Urology
Volume190
Issue number2
DOIs
StatePublished - Aug 2013
Externally publishedYes

Fingerprint

Castration
Prostatic Neoplasms
Guidelines
Controlled Vocabulary
Librarians
Androgen Antagonists
Patient Preference
Expert Testimony
Therapeutic Uses
Therapeutics
Palliative Care
Radioisotopes
Immunotherapy
Androgens
Meta-Analysis
Language
Observation
Bone and Bones
Drug Therapy
Health

Keywords

  • androgen antagonists
  • drug therapy
  • immunotherapy
  • prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Cookson, M. S., Roth, B. J., Dahm, P., Engstrom, C., Freedland, S. J., Hussain, M., ... Kibel, A. S. (2013). Castration-resistant prostate cancer: AUA guideline. Journal of Urology, 190(2), 429-438. https://doi.org/10.1016/j.juro.2013.05.005

Castration-resistant prostate cancer : AUA guideline. / Cookson, Michael S.; Roth, Bruce J.; Dahm, Philipp; Engstrom, Christine; Freedland, Stephen J.; Hussain, Maha; Lin, Daniel W.; Lowrance, William T.; Murad, Mohammad H; Oh, William K.; Penson, David F.; Kibel, Adam S.

In: Journal of Urology, Vol. 190, No. 2, 08.2013, p. 429-438.

Research output: Contribution to journalArticle

Cookson, MS, Roth, BJ, Dahm, P, Engstrom, C, Freedland, SJ, Hussain, M, Lin, DW, Lowrance, WT, Murad, MH, Oh, WK, Penson, DF & Kibel, AS 2013, 'Castration-resistant prostate cancer: AUA guideline', Journal of Urology, vol. 190, no. 2, pp. 429-438. https://doi.org/10.1016/j.juro.2013.05.005
Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M et al. Castration-resistant prostate cancer: AUA guideline. Journal of Urology. 2013 Aug;190(2):429-438. https://doi.org/10.1016/j.juro.2013.05.005
Cookson, Michael S. ; Roth, Bruce J. ; Dahm, Philipp ; Engstrom, Christine ; Freedland, Stephen J. ; Hussain, Maha ; Lin, Daniel W. ; Lowrance, William T. ; Murad, Mohammad H ; Oh, William K. ; Penson, David F. ; Kibel, Adam S. / Castration-resistant prostate cancer : AUA guideline. In: Journal of Urology. 2013 ; Vol. 190, No. 2. pp. 429-438.
@article{d4b91f48decc429baefaea0fe8608bcd,
title = "Castration-resistant prostate cancer: AUA guideline",
abstract = "Purpose: This Guideline is intended to provide a rational basis for the management of patients with castration-resistant prostate cancer based on currently available published data. Materials and Methods: A systematic review and meta-analysis of the published literature was conducted using controlled vocabulary supplemented with keywords relating to the relevant concepts of prostate cancer and castration resistance. The search strategy was developed and executed by reference librarians and methodologists to create an evidence report limited to English-language, published peer-reviewed literature. This review yielded 303 articles published from 1996 through 2013 that were used to form a majority of the guideline statements. Clinical Principles and Expert Opinions were used for guideline statements lacking sufficient evidence-based data. Results: Guideline statements were created to inform clinicians on the appropriate use of observation, androgen-deprivation and antiandrogen therapy, androgen synthesis inhibitors, immunotherapy, radionuclide therapy, systemic chemotherapy, palliative care and bone health. These were based on six index patients developed to represent the most common scenarios encountered in clinical practice. Conclusions: As a direct result of the significant increase in FDA-approved therapeutic agents for use in patients with metastatic CRPC, clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision-making more complex. Given the rapidly evolving nature of this field, this guideline should be used in conjunction with recent systematic literature reviews and an understanding of the individual patient's treatment goals. In all cases, patients' preferences and personal goals should be considered when choosing management strategies.",
keywords = "androgen antagonists, drug therapy, immunotherapy, prostatic neoplasms",
author = "Cookson, {Michael S.} and Roth, {Bruce J.} and Philipp Dahm and Christine Engstrom and Freedland, {Stephen J.} and Maha Hussain and Lin, {Daniel W.} and Lowrance, {William T.} and Murad, {Mohammad H} and Oh, {William K.} and Penson, {David F.} and Kibel, {Adam S.}",
year = "2013",
month = "8",
doi = "10.1016/j.juro.2013.05.005",
language = "English (US)",
volume = "190",
pages = "429--438",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Castration-resistant prostate cancer

T2 - AUA guideline

AU - Cookson, Michael S.

AU - Roth, Bruce J.

AU - Dahm, Philipp

AU - Engstrom, Christine

AU - Freedland, Stephen J.

AU - Hussain, Maha

AU - Lin, Daniel W.

AU - Lowrance, William T.

AU - Murad, Mohammad H

AU - Oh, William K.

AU - Penson, David F.

AU - Kibel, Adam S.

PY - 2013/8

Y1 - 2013/8

N2 - Purpose: This Guideline is intended to provide a rational basis for the management of patients with castration-resistant prostate cancer based on currently available published data. Materials and Methods: A systematic review and meta-analysis of the published literature was conducted using controlled vocabulary supplemented with keywords relating to the relevant concepts of prostate cancer and castration resistance. The search strategy was developed and executed by reference librarians and methodologists to create an evidence report limited to English-language, published peer-reviewed literature. This review yielded 303 articles published from 1996 through 2013 that were used to form a majority of the guideline statements. Clinical Principles and Expert Opinions were used for guideline statements lacking sufficient evidence-based data. Results: Guideline statements were created to inform clinicians on the appropriate use of observation, androgen-deprivation and antiandrogen therapy, androgen synthesis inhibitors, immunotherapy, radionuclide therapy, systemic chemotherapy, palliative care and bone health. These were based on six index patients developed to represent the most common scenarios encountered in clinical practice. Conclusions: As a direct result of the significant increase in FDA-approved therapeutic agents for use in patients with metastatic CRPC, clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision-making more complex. Given the rapidly evolving nature of this field, this guideline should be used in conjunction with recent systematic literature reviews and an understanding of the individual patient's treatment goals. In all cases, patients' preferences and personal goals should be considered when choosing management strategies.

AB - Purpose: This Guideline is intended to provide a rational basis for the management of patients with castration-resistant prostate cancer based on currently available published data. Materials and Methods: A systematic review and meta-analysis of the published literature was conducted using controlled vocabulary supplemented with keywords relating to the relevant concepts of prostate cancer and castration resistance. The search strategy was developed and executed by reference librarians and methodologists to create an evidence report limited to English-language, published peer-reviewed literature. This review yielded 303 articles published from 1996 through 2013 that were used to form a majority of the guideline statements. Clinical Principles and Expert Opinions were used for guideline statements lacking sufficient evidence-based data. Results: Guideline statements were created to inform clinicians on the appropriate use of observation, androgen-deprivation and antiandrogen therapy, androgen synthesis inhibitors, immunotherapy, radionuclide therapy, systemic chemotherapy, palliative care and bone health. These were based on six index patients developed to represent the most common scenarios encountered in clinical practice. Conclusions: As a direct result of the significant increase in FDA-approved therapeutic agents for use in patients with metastatic CRPC, clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision-making more complex. Given the rapidly evolving nature of this field, this guideline should be used in conjunction with recent systematic literature reviews and an understanding of the individual patient's treatment goals. In all cases, patients' preferences and personal goals should be considered when choosing management strategies.

KW - androgen antagonists

KW - drug therapy

KW - immunotherapy

KW - prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=84880009495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880009495&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2013.05.005

DO - 10.1016/j.juro.2013.05.005

M3 - Article

C2 - 23665272

AN - SCOPUS:84880009495

VL - 190

SP - 429

EP - 438

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -